Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.
about
Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung?Smoking, p53 mutation, and lung cancerInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaTumor suppressors and cell-cycle proteins in lung cancerMolecular pathways and therapeutic targets in lung cancerLung cancer. 9: Molecular biology of lung cancer: clinical implications.TP53 mutations in nonsmall cell lung cancerBiomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.The prognostic molecular markers in hepatocellular carcinoma.PICT1 expression is a poor prognostic factor in non-small cell lung cancer.Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancerA novel differential diagnostic model for multiple primary lung cancer: Differentially-expressed gene analysis of multiple primary lung cancer and intrapulmonary metastasisAdenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.How close are we to customizing chemotherapy in early non-small cell lung cancer?Lung cancer incidence and survival in chromium exposed individuals with respect to expression of anti-apoptotic protein survivin and tumor suppressor P53 protein.Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective studyAnalysis of cell cycle regulator proteins in non-small cell lung cancer.Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer.Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluationMolecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590.Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNAGenetic and biochemical alterations in non-small cell lung cancer.Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancerP53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancerSurvival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis.Sunlight may increase the FDG uptake value in primary tumors of patients with non-small cell lung cancer.The relationship between aberrant methylation and survival in non-small-cell lung cancers.The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis.Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancerConcordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.Biomarkers in lung cancer: from early detection to novel therapeutics and decision making
P2860
Q24801522-1B918813-795F-41C6-AB30-7E37CA25E40CQ27014977-06D5126D-CBBF-4226-9026-1A163B996F0FQ28303718-8CC963AC-B227-430D-A316-C6BC8A7E3D45Q28392478-D6399D8C-7FD6-464C-8D1C-4A4597ED1EB1Q33688872-12BFCE3E-12C1-4431-A8E9-724EDC2E298AQ33972805-E838FE9B-A63F-4770-B9B7-7FF136E57AAFQ34559185-BD3E5C6D-4D81-4681-A453-9CAA66D26604Q34623884-D02EEFF7-F89E-487F-9784-97D18AB703C7Q34668320-184A13E7-513A-46D0-A6CB-FA7D35BE665FQ34781290-9BD57D6F-9A3F-48B3-85D6-617D1DE73E97Q35032319-1A525ADE-72A4-4CFB-A7A7-B3D31C1C5340Q35042319-BD1A82F0-2FB8-4382-9984-3C560A4282C7Q35141514-5F4243BD-140B-4041-9A3B-5CA6ACE4888AQ35146944-DABC751D-2875-44F9-9CEC-C7700D64C021Q35179160-993DB8B1-2F26-4373-87A1-F92DCC065A5DQ35200402-1DFFEC12-FCF6-4F83-9962-8EAB9A9312CBQ35220347-6CF27004-06BF-4007-8C63-79DB8BDBDD05Q35536290-79DCBD58-0FE0-424B-892D-B0EC8E6957CCQ35556136-D0CF513A-2EF7-4215-81EB-37F7E5BB5647Q35587286-63B5C805-F1E3-43CB-BFB9-9F72E197CED6Q35588677-72022849-5D6D-4EF4-A4A7-41582D8C4B08Q35770249-B483A8D5-C6C9-4E3F-9C35-3D3FA2A6161BQ35828688-90B68DCF-CC76-40FD-A00F-3E22F5317C12Q35848114-E852CB4E-2EA6-4121-AF10-42DC59CEB623Q36049618-741DBE92-5E67-41D1-B00C-594DFC6652C4Q36128449-62F15680-5B5A-4C96-A7A5-03EB8276A130Q36184584-E6A5F6E6-C391-4272-9C7C-0B809A1A809EQ36188758-42836AF1-C813-4FA7-AA41-840D4EF6E536Q36308536-EA649687-A3AD-4118-AE67-DF9C114EED4CQ36311791-B208C5C6-F7BF-480B-B155-9CE3163D1F89Q36421289-2B2F2D75-D732-4150-99A0-7E46337D7BADQ36536565-7831E73A-0DEF-448D-AF12-E413395D88E4Q36616469-A9E5BAF6-656F-4842-8A27-501C460402A9Q36621221-08E59AB0-886E-4897-8A2A-E230F0F20983Q36626149-7BD65A60-1F28-4549-8251-DF0FA64F305DQ36642700-2D8030D1-5B29-43B6-9510-78D1877CC5BAQ36697794-CC1A3F1B-DAE0-40FD-A8BE-7A0513C17A79Q37126082-937D2FC8-D212-4213-B8DB-E88C61A0A731Q37175551-D3C8FBB1-C956-4074-AD37-8EA1EF5BC4FDQ37342919-7C507A06-CAB1-4544-847A-AB71FB522427
P2860
Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Prognostic significance of p53 ...... lung cancer: a meta-analysis.
@ast
Prognostic significance of p53 ...... lung cancer: a meta-analysis.
@en
Prognostic significance of p53 ...... lung cancer: a meta-analysis.
@nl
type
label
Prognostic significance of p53 ...... lung cancer: a meta-analysis.
@ast
Prognostic significance of p53 ...... lung cancer: a meta-analysis.
@en
Prognostic significance of p53 ...... lung cancer: a meta-analysis.
@nl
prefLabel
Prognostic significance of p53 ...... lung cancer: a meta-analysis.
@ast
Prognostic significance of p53 ...... lung cancer: a meta-analysis.
@en
Prognostic significance of p53 ...... lung cancer: a meta-analysis.
@nl
P2093
P1476
Prognostic significance of p53 ...... lung cancer: a meta-analysis.
@en
P2093
Hamajima N
Mitsudomi T
Takahashi T
P304
P407
P577
2000-10-01T00:00:00Z